Drug intelligence / Profile preview

paroxetine + lamotrigine

Development stage
Unknown
Lead developer
GSK
Modality
Small Molecules
Administration
Oral
01

Overview

Paroxetine + lamotrigine is a combination of two small molecule drugs used together, primarily in the treatment of depressive disorders, including unipolar and bipolar depression. Paroxetine is a selective serotonin reuptake inhibitor (SSRI) that increases synaptic serotonin levels by inhibiting its reuptake into presynaptic neurons, thereby exerting antidepressant and anxiolytic effects. Lamotrigine is an anticonvulsant and mood stabilizer that inhibits voltage-sensitive sodium channels, stabilizing neuronal membranes and modulating glutamate release; it has demonstrated efficacy in bipolar depression. The combination may accelerate the onset of antidepressant action compared to paroxetine alone and can be effective for core depressive symptoms[1][4]. There are no significant pharmacokinetic interactions between these agents, but additive central nervous system effects are possible[2].

02

Targets

NaV (Voltage-gated sodium channels)SERT (Sodium-dependent serotonin transporter)

Beyond the preview

Go deeper on paroxetine + lamotrigine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on paroxetine + lamotrigine.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call